Zoetis reported Q1 2026 revenue that missed analyst consensus estimates, driven by weaker-than-expected U.S. companion animal sales and increased competitive pressure across its dermatology and pain franchises. The company simultaneously reduced its FY 2026 organic operational revenue growth guidance from the previously issued range of 3% to 5%, citing soft U.S. pet-care demand and macro-economic headwinds. Shares closed down approximately 21.50% on heavy volume.
The magnitude of the market reaction reflected the gap between management's prior outlook and reported results. On the Q4 2025 earnings call in February 2026, CEO Kristin Peck had guided investors to expect 3% to 5% organic operational revenue growth for fiscal 2026. CFO Wetteny Joseph had also acknowledged that Q4 2025 international revenue included an approximate 2.5% to 3.5% one-time sales acceleration that the company did not expect to recur — a detail that made the subsequent miss and guidance cut even more significant to investors pricing the stock on forward expectations.
To receive more information, please fill out the form.
